[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351449-105":59,"doc-detail-351449-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","anti-cancer-immune-priming-with-radioligand-therapy-using-a-novel-high-affinity-antibody-selectively-targeting-the-4ig-isoform-of-b7-h3","Anti-cancer immune priming with β-radioligand therapy using a novel high affinity antibody selectively targeting the 4Ig-Isoform of B7-H3","","Radioligand therapy (RLT) is presented as an emerging cancer strategy that uses targeted radioisotopes to shrink tumors and improve survival, while also offering a route to influence systemic immunity. B7-H3 (CD276) is highlighted as a promising target, but selective engagement is challenged by two isoforms. A novel IgG2a antibody (MIL33B) was engineered for high-affinity binding to the 4Ig isoform and enhanced selectivity versus the soluble 2Ig decoy, enabling tumor-selective targeting and immune priming via CD8+ activation and memory.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/anti-cancer-immune-priming-with-radioligand-therapy-using-a-novel-high-affinity-antibody-selectively-targeting-the-4ig-isoform-of-b7-h3/351449/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/anti-cancer-immune-priming-with-radioligand-therapy-using-a-novel-high-affinity-antibody-selectively-targeting-the-4ig-isoform-of-b7-h3/351449.png","ImageObject",300,407,{"name":92,"@type":93},"Taylor Morgan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-08","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does this research address in radioligand therapy targeting B7-H3?","Question",{"text":112,"@type":113},"B7-H3 has two isoforms, a tumor-associated 4Ig and a soluble 2Ig decoy. The presence of the soluble isoform makes selective targeting difficult in the context of RLT.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was MIL33B designed to improve selectivity?",{"text":117,"@type":113},"MIL33B is an IgG2a monoclonal antibody developed to bind the 4Ig-B7-H3 isoform with high affinity (72 picomolar) and show 8-to-18-fold selectivity over soluble 2Ig-B7-H3.",{"name":119,"@type":110,"acceptedAnswer":120},"What immune-related outcome was observed after 90Y-MIL33B therapy?",{"text":121,"@type":113},"The study reports that 90Y-MIL33B acted as an immune priming event, engaging CD8+ T-cell activation and inducing immunological memory in addition to demonstrating survival benefit.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351449,1790198646,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099523885336,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Theranostics 2026, Vol. 16, Issue 10 5370  \nIvyspring  \nInternational Publisher  \nTheranostics  \n2026; 16(10): 5370-5392. doi: 10.7150/thno.123285  \nResearch Paper  \nAnti-cancer immune priming with β-radioligand therapy using a novel high affinity antibody selectively targeting the 4Ig-Isoform of B7-H3  \nSarah E. Glazer1\\#, Margie N. Sutton1\\#, Ping Yang1, Federica Pisaneschi1, Manu Sebastian2, Seth T. Gammon1􀀍, David Piwnica-Worms1􀀍  \n1. Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA.  \n2. Department of Veterinary Medicine & Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.  \n\\# Co-first authors.  \n􀀍 Corresponding authors: 1881 East Road, Unit 1907 Houston, TX 77054. Email addresses: [dpiwnica-worms@mdanderson.org](dpiwnica-worms@mdanderson.org); [stgammon@mdanderson.org](stgammon@mdanderson.org).  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2025.08.07; Accepted: 2026.01.13; Published: 2026.03.12  \nAbstract  \n\n| Rationale: Radioligand therapy (RLT) is an emerging oncologic strategy that uses molecularly targeted therapeutic radioisotopes to reduce tumor burden and improve survival in patients with advanced cancers. Expanding RLT to new targets and understanding its systemic immune effects could enhance its clinical impact. B7-H3 (CD276) is an attractive target due to its high differential expression in solid tumors compared to normal tissues. However, the presence of two isoforms, 4Ig-B7-H3 (tumor-associated) and 2Ig-B7-H3 (soluble decoy), poses challenges for selective targeting, especially in the context of RLT.\u003Cbr>Methods: A novel IgG2a monoclonal antibody (MIL33B) was developed with high affinity for 4Ig-B7-H3 (72 picomolar) and 8-to 18-fold selectivity over soluble 2Ig-B7-H3. Target specificity was assessed using live-cell fluorescence microscopy with AF594-labeled MIL33B. In vivo tumor binding was evaluated by PET-CT imaging with 89Zr-labeled MIL33B in murine xenograft (HeLa cervical) and syngeneic tumor models (4T1 breast, B16F10 melanoma, CT26 colorectal) expressing human 4Ig-B7-H3. Therapeutic efficacy was tested using 90Y-labeled MIL33B (100 μCi) in an established CT26 colorectal tumor model. Immunologic effects were analyzed to assess CD8+ T-cell activation and immune memory.\u003Cbr>Results: MIL33B demonstrated strong membranous localization using live cell fluorescence microscopy. PET-CT imaging with 89Zr-labeled MIL33B confirmed robust tumor-selective binding in vivo. A single systemic dose of 90Y-MIL33B achieved 53% long-term survival in a 4Ig-B7-H3-dependent manner in an otherwise fatal CT26 colorectal syngeneic tumor model. Immunologic analysis revealed that 90Y-MIL33B RLT acted as an immune priming event, engaging CD8+ T-cell activation and inducing immunological memory.\u003Cbr>Conclusions: MIL33B enables selective targeting of 4Ig-B7-H3 for beta-emitting RLT, overcoming challenges posed by soluble isoforms. These findings support further investigation of MIL33B as a systemic therapeutic with immune-priming potential, either alone or in combination strategies for cancer treatment. |  |\n| --- | --- |\n| Introduction |  |\n| Radiotheranostics, also referred to as radioligand | primary tumor, and in some applications, to |\n| therapy (RLT), functions as a systemic modality | oligometastatic disease [2], but many patients present |\n| designed to eradicate primary tumors, disseminated | with distant macro- and micro-metastases and |\n| metastases, and occult micrometastatic disease | continuously shed detectable levels of circulating |\n| through targeted delivery of cytotoxic radiation | tumor cells into the systemic circulation outside the |\n| (Figure 1A) [1]. By comparison","cbCaihSwTcglkBNn","https://ap.wps.com/l/cbCaihSwTcglkBNn","pdf",6420522,23,"English","# Abstract\n## Rationale\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What problem does this research address in radioligand therapy targeting B7-H3?\",\"answer\":\"B7-H3 has two isoforms, a tumor-associated 4Ig and a soluble 2Ig decoy. The presence of the soluble isoform makes selective targeting difficult in the context of RLT.\"},{\"question\":\"How was MIL33B designed to improve selectivity?\",\"answer\":\"MIL33B is an IgG2a monoclonal antibody developed to bind the 4Ig-B7-H3 isoform with high affinity (72 picomolar) and show 8-to-18-fold selectivity over soluble 2Ig-B7-H3.\"},{\"question\":\"What immune-related outcome was observed after 90Y-MIL33B therapy?\",\"answer\":\"The study reports that 90Y-MIL33B acted as an immune priming event, engaging CD8+ T-cell activation and inducing immunological memory in addition to demonstrating survival benefit.\"}]","Anti-cancer immune priming with β-radioligand therapy using a novel high affinity antibody selectively targeting the 4Ig-Isoform of B7-H3 | PDF",1790094204,58,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/336795c48ab6d139592692fc2fee6e58.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/93909c663c3fc6407f16ed1b1a97ba63.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c3a45c2953b3cf648fde013ab85e86b3.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/486d48f10f1313b7f770cab9df8f34b2.webp",980,1268]